Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZEN003694 + capecitabine
- Development stage
- Unknown
- Lead developer
- Zenith Epigenetics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZEN003694 + capecitabine is an investigational combination therapy being evaluated for the treatment of metastatic or unresectable solid tumors, including colorectal cancer. ZEN003694 (ZEN-3694) is an orally bioavailable small molecule inhibitor of the bromodomain and extra-terminal (BET) family of proteins. By binding to the acetyl-lysine binding pockets of BET proteins (such as BRD2, BRD3, and BRD4), ZEN003694 prevents their interaction with acetylated histones, thereby modulating the expression of genes involved in cell cycle progression and apoptosis. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), an antimetabolite that interferes with DNA synthesis and slows tumor growth. This combination therapy is currently being studied in Phase I clinical trials sponsored by the National Cancer Institute (NCI) to determine safety, tolerability, and the recommended Phase II dose in patients who have progressed on standard therapies.
- Brand names
- Xeloda
- Other names
- ZEN-3694 + capecitabine
02
Targets
BRD2 (Bromodomain-containing protein 2)BRD3 (Bromodomain-containing protein 3)TS (Thymidylate synthase)BRD4 (Bromodomain-containing protein 4)
Beyond the preview
Go deeper on ZEN003694 + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZEN003694 + capecitabine.